ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Oncogene Ročník 37; číslo 33; s. 4611 - 4625
Hlavní autoři:	Berns, Katrien, Caumanns, Joseph J., Hijmans, E. Marielle, Gennissen, Annemiek M. C., Severson, Tesa M., Evers, Bastiaan, Wisman, G. Bea A., Jan Meersma, Gert, Lieftink, Cor, Beijersbergen, Roderick L., Itamochi, Hiroaki, van der Zee, Ate G. J., de Jong, Steven, Bernards, René
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.08.2018 Nature Publishing Group
Témata:	13/1 13/106 13/109 13/51 13/89 14/63 38/23 38/47 45/15 631/154/555 631/67/1517/1709 96/44 Apoptosis Cancer Cancer cells Carcinoma Care and treatment Cell Biology Development and progression Disease management Gene mutation Genetic aspects Health aspects Human Genetics Innovations Internal Medicine Lethality Medical research Medical schools Medicine Medicine & Public Health Molecular targeted therapy Mutation Oncology Ovarian cancer Ovarian carcinoma Patients Proteins Tumor cell lines Xenografts
ISSN:	0950-9232, 1476-5594, 1476-5594
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!